ClinicalTrials.gov
ClinicalTrials.gov Menu

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02477800
Recruitment Status : Recruiting
First Posted : June 23, 2015
Last Update Posted : May 15, 2018
Sponsor:
Information provided by (Responsible Party):
Biogen

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : November 18, 2019
  Estimated Study Completion Date : March 5, 2022